The Center for Drug Evaluation (CDE) has released a set of Technical Guidelines focused on “Clinical R&D of Anti-tumor Drugs for Children,” which are now in immediate effect. These guidelines were drafted to address the specific needs and considerations in the development of anti-tumor drugs for pediatric patients.<\/p>\n\n\n\n
Public Consultation and the Need for Pediatric Anti-tumor Drugs<\/strong> Key Considerations in Pediatric Anti-tumor Drug Clinical Plans<\/strong>
The draft proposal for these guidelines was released in November of the previous year to solicit public feedback. Pediatric anti-tumor drugs have been relatively neglected compared to adult anti-tumor drugs in research and development. There are significant differences between child and adult tumors in terms of pathogenesis, tissue source, and driving gene changes, which result in different disease types, symptoms, and treatment plans.<\/p>\n\n\n\n
When formulating clinical plans for pediatric anti-tumor drugs, the following must be taken into consideration:<\/p>\n\n\n\n